Hsa-miR-3651 could serve as a novel predictor for in-breast recurrence via FRMD3.

Barbara ZellingerUlrich BodenhoferImmanuela A EngländerCornelia KronbergerBrane GrambozovElvis RuznicMarkus StanaJosef KarnerGerd FastnerKarl SotlarFelix SedlmayerFranz Zehentmayr

Published in: Breast cancer (Tokyo, Japan) (2021)

The current study revealed that hsa-miR-3651 is a predictor of LC in early breast cancer via its putative target protein FRMD3. Since microRNAs interfere in multiple pathways, the results of this hypothesis generating study may contribute to the development of tailored therapies for breast cancer in the future.

Keyphrases

cell proliferation
long non coding rna
early breast cancer
long noncoding rna
mass spectrometry
single cell
smoking cessation
free survival
high resolution mass spectrometry